Member Info for inanaco

scancell

MouseGate

Update """" we can effectively establish a ‘human’ tumour model""""

MODI-1 vaccines have been extremely successful
in animal studies with transgenic mice expressing
human MHC II. Both vimentin and a-enolase peptides
individually have been shown to induce immune
responses against tumours in HLA-DR4 transgenic mice.
Since these mice are expressing HLA-DR4 (a human MHC
II molecule) we can effectively establish a ‘human’ tumour
model and investigate the interaction between human
CD4 T cells and human tumour in vivo. Vimentin peptides
induced a strong CD4 anti-tumour response leading to
the survival of 80% of transgenic mice. Vaccination with
just a-enolase also showed significant survival against a
number of tumour types including melanoma, and those
in the lung and pancreas. Furthermore, CD4-specific
responses were also observed when these peptides were
tested in vitro using PBMCs from healthy individuals with
several HLA types. The results from PMBCs proliferation
assays suggest the citrullination-specific response is not
restricted to just one HLA type, hence the vaccine can be
used in a wider population. Clinical trials with MODI-1
are now being designed.

did you know that Lindy was an expert on Chemo ? just been browsing .... PhD in Cancer Chemotherapy at Paterson Institute of Cancer Research ...

Genexine’s HPV Therapeutic DNA Vaccine, GX-188E in Combination with KEYTRUDA® (pembrolizumab) enters into Stage 2 of Phase II Cervical Cancer Trial
Genexine Inc., a clinical stage biotechnology company developing innovative biologics, announced that GX-188E in combination with KEYTRUDA® (pembrolizumab) Phase II cervical cancer trial is entering into Simon Stage 2, after achieving targeted response rate in Stage 1. This study was initiated in May 2018, targeting patients with HPV (Human Papilloma Virus)-induced recurrent, relapsed, and metastatic cervical cancer.

The study is being conducted in seven major hospitals in Korea, including Seoul St. Mary’s Hospital, Asan Medical Center, and the National Cancer Center. Genexine and Merck & Co., Inc., Kenilworth, N.J., USA.adopted the Simon two-stage design, which mandates to see a response rate from at least 3 patients in Stage 1 out of maximum 15 patients enrolled. The response is defined as either complete or partial remission of cancer, indicated by the reduction of tumor size by a specific percentage. Genexine and Merck & Co., Inc., Kenilworth, N.J., USA.agreed to enter the Stage 2 earlier than planned after evaluating responses from 10 patients instead of 15, as the target response rate in Stage 1 was met including one of the patients showing complete response (CR). The study design allows enrolling total 28 patients for the Stage 2.

what would that indicate for Scancell ?????

well here is a clue

http://www.genexine.com/m22.php

Knowlesi ...

when you talk about de-risked and risk

what are you actually identifying as the risk ?

even NASA runs a "what if" .. scenario

what is yours to find Apollo 13 ?

come up with a sensible identifiable "position" rather than it must be bad because Val did not buy into scancell

which point is real ? TF

can you expand that a bit ..

you may have contempt for the share ... but you are now targeting investors who you feel are being mugged in scancell

yet Knowlesi is a long term shareholder ...

having unbiased opinion (free of personal share dealing manipulation) is welcome ...

indeed i welcome the challenge

but Knowlesi has already confessed to wanting to "buy"

your behind the curve and you have jumped on a bandwagon with no wheels

go to member .. click on Post distribution .. so Nom has posted 4 times on scancell in the same period 50 times on VAL

so reliable

coming from the VAL bb .. you are the expert Nom

Chester18 ......... Knowlesi is a Holder of Scancell but is "underwater" ... he was trying to buy in Sub 3p to lower his average ...

its a game .. of Poker it always has been ..

and the biggest threat to a poker player is me ........ because i dig in !! identify motive ...

that generated a response by Knowlesi "bazooka " which is why i get so much stick .. i identified him as a market manipulator ...

to the point that he point £4m in at 5p

punted .. LOL

Knowlesi never posts on the science for the simple reason he cannot put forward a statement or evidence that the science has failed, but its far easier to portray Scancell as an "average" ie club all the pharma together and assume all the risks of the average .... then imply that scancell had "deadlines" rather than time estimates, which fuels the Doom and Gloom merchants.
The biggest weapon used to attack the share was "funding" and that spectacular price rise from 4p to 9p was fueled by funding. So that also failed.

What is interesting Diggles did not dive into the market at 3.6p considering he would know by then for sure and investment was highly likely, probably because of "insider information" but he also did not insist that the fund would only buy sub 4p !! even thou the share prior had been in that range. but instead paid 5p and described it as "undervalued" in effect he would have paid more if the market had valued Scancell at what he considered "fair Market"

so it continues ... even MiceGate ....

scancell developed a mouse just for testing Moditope ........... so you could never apply an industry average mouse as a comparison of Mouse to human results

But the Doom and Gloom boys insisted that the average Mouse data should be applied and indeed play down the value of mouse data as "highly risky"

but when you suggest that SCIB1 mouse data has translated into the clinic ....... the combo scib1/keytruda data should be considered "highly risky" ... despite the mechanism of interaction between Keytruda and SCIB1 being synergistic

so this is what you are up against ........... Scancell gets bundled with all the industry failures and the Odd success as an "average"

rather than the very specific identification of the science as "undervalued" which was carried out by Diggles Due Diligence

to the point that he point £4m in at 5p .... and Knowlesi forgot to buy at 3.6p

who is the mug ?

yea why not its the mathematical modeling of T cells

the maths

https://www.pnas.org/content/116/13/5914

even down to a reminder that Keytruda works on the T-Cells not the cancer, just the small things..........

and that is the most Important thing ......................

which is why i cannot find a mechanism of failure .. as Synergy exists between Pd-1 and T cells ...

so you look at what your T cells can do if they are not turned off by Cancer .....

the Trial will reveal all ...

I would also point out, to this point in time Scancell has not failed ....

have you any of you evidence that it will ? or does Project Fear Grip the investment community ...

question i would love to know

has Ruck sold ?

you see holding for a deal knowing it might fail is not different to holding for a deal when you consider it will not fail

the only difference one party has "stressed" himself out for years

while the Other "studies" the science behind the belief

i know which camp i am in ...

i never posted Scancell cannot Fail I posted

Scancell cannot fail ............ SCIB1 has generated the "exact " type of T cell that has extremely High affinity to Bonding

so cannot fail related directly to scib1 t cells proven in trial

this article shows how PD-1 like Keytruda will engage with High Avidity T cells like those generated by Immunobody

""""" upon anti–PD-1 therapy, our work describes the emergence of high-avidity Melan-A–specific clonotypes as a surrogate marker of treatment efficacy""""""""""

Therapeutic strategies using anti–PD-1–blocking antibodies reported unparalleled effectiveness for melanoma immunotherapy, but deciphering immune responses modulated by anti–PD-1 treatment remains a crucial issue. Here, we analyzed the composition and functions of the large Melan-A–specific T-cell repertoire in the peripheral blood of 9 melanoma patients before and after 2 months of treatment with anti–PD-1. We observed amplification of Melan-A–specific Vß subfamilies undetectable before therapy (thereafter called emerging Vß subfamilies) in responding patients, with a predominant expansion in patients with a complete response. These emerging Vß subfamilies displayed a higher functional avidity for their cognate antigen than Vß subfamilies not amplified upon anti–PD-1 therapy and could be identified by a sustained coexpression of PD-1 and TIGIT receptors. Thus, in addition to the emergence of neoantigen-specific T cells previously documented upon anti–PD-1 therapy, our work describes the emergence of high-avidity Melan-A–specific clonotypes as a surrogate marker of treatment efficacy. Cancer Res; 77(24); 7083–93. ©2017 AACR

https://www.pnas.org/content/111/4/1485

so while i am showing Scancell has

1/ High Avidity
2/ Tested in Humans
3/ Generated Memory
4/ Has exposure to Checkpoints in humans
5/ Has validation from Cancer Research

what exactly have you got Ruck and Knowlesi ?

nothing

here is another one for you .............. again "high Avidity"

"""""This high-resolution analysis showed reproducible enrichment (or diminution) of particular TCR clonotypes across all challenged animals. These changes in clonal composition were TCRa- and ß chain–dependent and were directly related to the avidity of the TCR for the virus-derived peptide (p) + major histocompatibility complex class I molecule. """"

in other words the memory T cells generated that the body squirreled away are "the Best" of the bunch to use at some point in a re-challenge

High Avidity ....

https://www.pnas.org/content/111/4/1485

Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection